Historical benchmarks for medical therapy trials in surgery-and radiation-refractory meningioma: A RANO review

Neuro-Oncology

Volumn 16, Issue 6, 2014, Pages 829-840

  Kaley, Thomas ^a   Barani, Igor ^b   Chamberlain, Marc ^c   McDermott, Michael ^d   Panageas, Katherine ^a   Raizer, Jeffrey ^e   Rogers, Leland ^f   Schiff, David ^g   Vogelbaum, Michael ^h   Weber, Damien ⁱ   Wen, Patrick ^j  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f GammaWest Cancer Services   (United States)

^g UNIVERSITY OF VIRGINIA   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

anaplastic meningioma; atypical meningioma; chemotherapy meningioma; malignant meningioma; meningioma

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; ERLOTINIB; GEFITINIB; HYDROXYUREA; IMATINIB; IRINOTECAN; MEGESTROL ACETATE; MIFEPRISTONE; OCTREOTIDE; TEMOZOLOMIDE;

ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; HUMAN; MALIGNANT MENINGIOMA; MEDLINE; MENINGIOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PILOT STUDY; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; MENINGEAL NEOPLASMS; QUALITY CONTROL; SURVIVAL;

BENCHMARKING; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84900804532     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not330     Document Type: Article

References (51)

1. Wen PY, Quant E, Drappatz J, et al. Medical therapies for meningiomas. J Neurooncol. 2010;99:365-378.
2. Norden AD, Drappatz J, Phuphanich S, et al. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. J Clin Oncol. 2011;29 (suppl; abstr 2040).
3. Chamberlain MC. Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg. 1996;84:733-736.
4. Chamberlain MC. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J Neurooncol. 2012;107: 315-321.
5. Chamberlain MC, Glantz MJ. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer. 2008;113:2146-2151.
6. Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007;69:969-973.
7. Chamberlain MC, Johnston SK. Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. J Neurooncol. 2011;104:765-771.
8. Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology. 2004;62: 1210-1212.
9. Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol. 2006;78: 271-276.
10. Chen TC, Chamberlain MC. Adjuvant therapy for unresectable meningiomas: benign and malignant. Neurosurg Focus. 2007;23:1.
11. Garcia-Luna PP, Relimpio F, Pumar A, et al. Clinical use of octreotide in unresectable meningiomas. A report of three cases. J Neurosurg Sci. 1993;37:237-241.
12. Goodwin JW, Crowley J, Eyre HJ, et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol. 1993;15:75-77.
13. Goutagny S, Raymond E, Sterkers O, et al. Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol. 2011;22:990-991.
14. Grunberg SM. The role of progesterone receptors in meningioma. Cancer Treat Res. 1991;58:127-137.
15. Grunberg SM, Daniels AM, Muensch H, et al. Correlation of meningioma hormone receptor status with hormone sensitivity in a tumor stem-cell assay. J Neurosurg. 1987;66:405-408.
16. Grunberg SM, Weiss MH. Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J Neurooncol. 1990;8: 61-65.
17. Grunberg SM, Weiss MH, Russell CA, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006;24:727-733.
18. Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg. 1991;74:861-866.
19. Hahn BM, Schrell UM, Sauer R, et al. Prolonged oral hydroxyurea and concurrent 3D-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J Neurooncol. 2005; 74:157-165.
20. Jaaskelainen J, Laasonen E, Karkkainen J, et al. Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA). A pilot study of five cases. Acta Neurochir (Wien). 1986;80: 35-41.
21. Jaffrain-Rea ML, Minniti G, Santoro A, et al. Visual improvement during octreotide therapy in a case of episellar meningioma. Clin Neurol Neurosurg. 1998;100:40-43.
22. Johnson DR, Kimmel DW, Burch PA, et al. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol. 2011;13:530-535.
23. Kaba SE, DeMonte F, Bruner JM, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery. 1997;40:271-275.
24. Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib (SU011248) for recurrent meningioma. Neuro Oncol. 2010;12:iv75-iv76.
25. Swinnen LJ, Rankin C, Rushing EJ, et al. Phase II study of hydroxyurea for unresectable meningioma (Southwest Oncology Group S9811). J Clin Oncol. 2009;27(15s) (suppl; abstr 2063).
26. Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012;109:63-70.
27. Loven D, Hardoff R, Sever ZB, et al. Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol. 2004;67: 221-226.
28. Markwalder T, Seiler R, Zava D. Antiestrogenic therapy of meningiomas-a pilot study. Surg Neurol. 1985;24:245-249.
29. Mason WP, Gentili F, Macdonald D, et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg. 2002;97:341-346.
30. Muhr C, Gudjonsson O, Lilja A, et al. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res. 2001;7:2269-2276.
31. Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012;109: 187-193.
32. Newton HB, Slivka MA, Stevens C. Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol. 2000;49: 165-170.
33. Norden A, Drappatz J, Wen P. Advances in meningioma therapy. Curr Neurol Neurosci Rep. 2009;9:231-240.
34. Norden A, Raizer J, Abrey L, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010;96: 211-217.
35. Paus S, Klockgether T, Urbach H, et al. Meningioma of the optic nerve sheath: treatment with hydroxyurea. J Neurol Neurosurg Psychiatry. 2003;74:1348-1350.
36. Puchner MJ, Hans VH, Harati A, et al. Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol. 2010;21:2445-2446.
37. Raizer JJ, Abrey LE, Lassman AB, et al. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol. 2010;12:87-94.
38. Reardon DA, Norden AD, Desjardins A, et al. Phase II study of Gleevecw plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol. 2012;106:409-415.
39. Rosenthal MA, Ashley DL, Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci. 2002;9:156-158.
40. Runzi MW, Jaspers C, Windeck R, et al. Successful treatment of meningioma with octreotide. Lancet. 1989;1:1074.
41. Runzi MW, Jaspers C, Windeck R, et al. Treatment of meningioma with octreotide. Lancet. 1989;2:217-218.
42. Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg. 1997;86:840-844.
43. Steven M, Grunberg CR, Townsend J. Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. Proc Am Soc Clin Oncol. 2001(abstr 222). 20 (suppl; abstr 2040).
44. Wen PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium study 99-08. Clin Cancer Res. 2006;12: 4899-4907.
45. Wen PY, Yung WK, Lamborn KR, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol. 2009;11:853-860.
46. Weston GJ, Martin AJ, Mufti GJ, et al. Hydroxyurea treatment of meningiomas: a pilot study. Skull Base. 2006;16:157-160.
47. Wilson TJ, Heth JA. Regression of a meningioma during paclitaxel and bevacizumab therapy for breast cancer. J Clin Neurosci. 2012; 19:468-469.
48. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
49. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol. 2010;28:1963-1972.
50. Quant EC, Wen PY. Response assessment in neuro-oncology. Curr Oncol Rep. 2011;13:50-56.
51. Raizer JJ, Grimm S, Chandler J, et al. A phase II trial of PTK787/ZK 222584 (PTK787) in recurrent or progressive meningiomas. Neuro-Oncol. 2010;12(s4):iv75.